EXPRESSION OF BCL-2 GENE-PRODUCT IN NEUROBLASTOMA

被引：49

作者：

RAMANI, P ^{[1
]}

LU, QL ^{[1
]}

机构：

[1] IMPERIAL CANC RES FUND,ROYAL COLL SURGEONS ENGLAND,HISTOPATHOL UNIT,LONDON WC2A 3PX,ENGLAND

来源：

JOURNAL OF PATHOLOGY | 1994年 / 172卷 / 03期

关键词：

BCL-2; IMMUNOREACTIVITY; NEUROBLASTOMA;

D O I：

10.1002/path.1711720308

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The expression of bcl-2 is associated with inhibition of apoptosis and prolonged cell survival. The purpose of this study was to examine the immunoreactivity of neuroblastoma and ganglioneuroblastoma tissue samples to the bcl-2 gene product in order to see if it was related to prognosis. BCL-2 protein was detected in all the 46 formalin-fixed, paraffin-embedded samples from 34 patients representing all clinical stages and sites of involvement. Immunopositivity was observed in tumours from the primary and metastatic sites. Moreover, it was demonstrated in the pre-chemotherapy and the post-chemotherapy samples from six cases with stage 4 disease. It was observed in neuroblasts in various stages of differentiation. A small proportion of undifferentiated neuroblasts were negative. As BCL-2 oncoprotein was present in all the cases irrespective of the clinical outcome, it does not appear to be one of the factors influencing prognosis.

引用

页码：273 / 278

页数：6

共 32 条

[1]

Beckwith J B, 1968, J Pediatr Surg, V3, P106

[2]

BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO

[3]

2-H

[4] INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].

BRODEUR, GM ;

SEEGER, RC ;

BARRETT, A ;

BERTHOLD, F ;

CASTLEBERRY, RP ;

DANGIO, G ;

DEBERNARDI, B ;

EVANS, AE ;

FAVROT, M ;

FREEMAN, AI ;

HAASE, G ;

HARTMANN, O ;

HAYES, FA ;

HELSON, L ;

KEMSHEAD, J ;

LAMPERT, F ;

NINANE, J ;

OHKAWA, H ;

PHILIP, T ;

PINKERTON, CR ;

PRITCHARD, J ;

SAWADA, T ;

SIEGEL, S ;

SMITH, EI ;

TSUCHIDA, Y ;

VOUTE, PA .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881

[5] GENE AMPLIFICATION AND DRUG-RESISTANCE [J].

BROWN, R .

JOURNAL OF PATHOLOGY, 1991, 163 (04) :287-292

[6] P-GLYCOPROTEIN EXPRESSION AS A PREDICTOR OF THE OUTCOME OF THERAPY FOR NEUROBLASTOMA [J].

CHAN, HSL ;

HADDAD, G ;

THORNER, PS ;

DEBOER, G ;

LIN, YP ;

ONDRUSEK, N ;

YEGER, H ;

LING, V .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) :1608-1614

[7]

EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO

[8]

2-F

[9] PREVENTION OF PROGRAMMED CELL-DEATH OF SYMPATHETIC NEURONS BY THE BCL-2 PROTOONCOGENE [J].

GARCIA, I ;

MARTINOU, I ;

TSUJIMOTO, Y ;

MARTINOU, JC .

SCIENCE, 1992, 258 (5080) :302-304

[10]

HAMMOND G D, 1986, Cancer, V58, P407, DOI 10.1002/1097-0142(19860715)58:2+<407::AID-CNCR2820581302>3.0.CO

← 1 2 3 4 →